Endocrine Abstracts

During menopause, plasma lipids change in an unfavourable way to a more atherogenic pattern with, increased total and LDL-cholesterol and decreased HDL cholesterol concentrations. Women with POI show increased cardiovascular morbidity and mortality regardless of the cause of the ovarian insufficiency. The treatment of premature ovarian failure in patients presenting extremely low HLD-C is a real challenge.We present the case of a 29 ye...

During menopause, plasma lipids change in an unfavourable way to a more atherogenic pattern with, increased total and LDL-cholesterol and decreased HDL cholesterol concentrations. Women with POI show increased cardiovascular morbidity and mortality regardless of the cause of the ovarian insufficiency. The treatment of premature ovarian failure in patients presenting extremely low HLD-C is a real challenge.We present the case of a 29 ye...

Although it is well known that aplastic anemia and agranulocytosis are potential lethal adverse reactions of antithyroid treatment, we present a case of methimazole administration in a patient with bone marrow transplant for multiple myeloma, with favorable evolution. We present the case of a 43 y.o. male, known with Grave’s disease since 2010 (on ATS treatment for only 6 months), vitiligo, systemic sclerosis and type 1 diabetes, diagnosed with multiple mieloma Ig G Tipe,...

Resistance to thyroid hormones (RTH) is a genetic syndrome characterized by reduced responsiveness of target tissues to thyroid hormones (TH) and accompanied by normal or slightly high TSH values with high serum concentrations of fT4 or fT3. We present two cases of RTH, one pituitary and one generalised resistance.Case 1: A 31 y.o. male presented with thyrotoxicosis symptoms and a biochemical profile showing increased serum fT4...

Introduction: Follicle-stimulating hormone (FSH) and its corresponding receptor (FSHR) are essential factors for regular gonadal development, sexual maturation at puberty and gamete production during the fertile period in both sexes. The FSHR encoding gene was mapped to the short arm of chromosome (CR) 2 in 2p16.3.3 In females, inactivating mutations result clinically – depending on the degree of inactivation – in primary amenorrhea, sec...

Introduction: Follicle-stimulating hormone (FSH) and its corresponding receptor (FSHR) are essential factors for regular gonadal development, sexual maturation at puberty and gamete production during the fertile period in both sexes. The FSHR encoding gene was mapped to the short arm of chromosome (CR) 2 in 2p16.3.3 In females, inactivating mutations result clinically – depending on the degree of inactivation – in primary amenorrhea, sec...

Adrenal carcinoma is a very rare malignancy accounting for 0.05–0.2% of all cancers, with an incidence 0.5–2/106.We present the case of a 60 year old woman with impaired fasting glucose and hypertension, who was incidentally diagnosed, after a non-enhanced abdominal CT, with a right adrenal tumor of 4.5/6 cm. The mass was described as having smooth borders, and a heterogeneous aspect including solid parts, necrotic areas and 1 microc...

Giant prolactinomas are rare pituitary tumors, defined as adenomas greater than 4 cm, with extrasellar extension, presenting with PRL levels > 1000 ng/dl. Dopamine agonists (DA) are the first-line treatment. Most (90%) of giant prolactinomas occur in men.We describe two cases of giant prolactinoma. A 17 years man presented with frontal headache, gradual visual deficit, nausea and dizziness. MRI demonstrated a sellar tumor of 6.4 cm with extrasellar e...

Introduction: Von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant syndrome manifested by a variety of benign and malignant tumors, with an incidence of about 1 in 36 000 individuals and a mean age at presentation of 26 years.We present a family (mother and daughter) case of possible type 2A VHL disease diagnosed with multiple VHL-associated tumors in the absence of an available genetic testing. They both presented in our clinic in 2013 wi...

Objective: To determine if the response to one single dose of 0.5 mg cabergoline (CAB) can be used as predictor for choosing personalized therapy of hyperprolactinaemia. Although CAB is a selective, long half-life D2-receptor agonist some patients proved to be resistant with minimum to no response in serum prolactin and tumour shrinkage, even after a few months of treatment.Patients and methods: A dose of 0.5 mg CAB was administered orally to a number of...